Meta-analysis of expression of hepatic organic anion-transporting polypeptide (OATP) transporters in cellular systems relative to human liver tissue

Drug Metabolism and Disposition

Volumn 43, Issue 4, 2015, Pages 424-432

  Badée, Justine ^a   Achour, Brahim ^a   Rostami Hodjegan, Amin ^a,b   Galetin, Aleksandra ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ORGANIC ANION TRANSPORTER B; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; DRUG; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN; SLCO1B3 PROTEIN, HUMAN; SLCO2B1 PROTEIN, HUMAN;

AGE; ARTICLE; CELL MIGRATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; SEX DIFFERENCE; AGING; BIOSYNTHESIS; CULTURE TECHNIQUE; CYTOLOGY; LIVER; LIVER CELL; META ANALYSIS; METABOLISM; PROCEDURES; PROTEOMICS; STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA; TISSUE DISTRIBUTION;

AGING; CELL CULTURE TECHNIQUES; DATA INTERPRETATION, STATISTICAL; HEPATOCYTES; HUMANS; LIVER; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PHARMACEUTICAL PREPARATIONS; PROTEOMICS; TISSUE DISTRIBUTION;

EID: 84939781080     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.062034     Document Type: Article

References (41)

1. Achour B, Barber J, and Rostami-Hodjegan A (2014) Expression of hepatic drug-metabolizing cytochrome p450 enzymes and their intercorrelations: a meta-analysis. Drug Metab Dispos 42: 1349-1356.
2. Armitage P, Berry G, and Matthews JNS (2001) Statistical methods in medical research. Blackwell Science, Malden, MA.
3. Balogh LM, Kimoto E, Chupka J., Zhang H, and Lai Y (2012) Membrane Protein Quantification by Peptide-Based Mass Spectrometry Approaches: Studies on the Organic Anion-Transporting Polypeptide Family. J Proteomics Bioinform S4:003.
4. Bi YA, Kimoto E, Sevidal S., Jones HM, Barton HA, Kempshall S, Whalen K.M., Zhang H., Ji C, and Fenner KS, et al. (2012) In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation. Drug Metab Dispos 40:1085-1092.
5. Bow DA, Perry JL, Miller D.S., Pritchard JB, and Brouwer KL (2008) Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes. Drug Metab Dispos 36:198-202.
6. Choi JH, Murray JW, and Wolkoff AW (2011) PDZK1 binding and serine phosphorylation regulate subcellular trafficking of organic anion transport protein 1a1. Am J Physiol Gastro-intest Liver Physiol 300:G384-G393.
7. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10: 101-129.
8. Galetin A (2014) Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling. Methods Mol Biol 1113:255-288.
9. Gardiner P and Paine SW (2011) The impact of hepatic uptake on the pharmacokinetics of organic anions. Drug Metab Dispos 39:1930-1938.
10. Gertz M, Cartwright CM, Hobbs M.J., Kenworthy KE, Rowland M, Houston JB, and Galetin A (2013) Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential. Pharm Res 30:761-780.
11. Gertz M, Tsamandouras N, Säll C, Houston J.B., and Galetin A (2014) Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk. Pharm Res 31: 2367-2382.
12. Giacomini KM, Huang SM, Tweedie D.J., Benet LZ, Brouwer KL, Chu X, Dahlin A., Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
13. Gong IY and Kim RB (2013) Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet 28:4-18.
14. Harwood MD, Russell MR, Neuhoff S, Warhurst G., and Rostami-Hodjegan A (2014) Lost in centrifugation: accounting for transporter protein losses in quantitative targeted absolute pro-teomics. Drug Metab Dispos 42:1766-1772.
15. Higgins JP and Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
16. Higgins JP, Thompson SG, Deeks J.J., and Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560.
17. Hirano M, Maeda K, Shitara Y., and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139-146.
18. Jamei M, Bajot F, Neuhoff S., Barter Z, Yang J, Rostami-Hodjegan A, and Rowland-Yeo K (2014) A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet 53:73-87.
19. Ji C, Tschantz WR, Pfeifer N.D., Ullah M., and Sadagopan N (2012) Development of a multiplex UPLC-MRM MS method for quantification of human membrane transport proteins OATP1B1, OATP1B3 and OATP2B1 in in vitro systems and tissues. Anal Chim Acta 717:67-76.
20. Jones HM, Barton HA, Lai Y, Bi Y.A., Kimoto E., Kempshall S, Tate SC, El-Kattan A, Houston J.B., and Galetin A, et al. (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007-1017.
21. Karlgren M, Vildhede A, Norinder U., Wisniewski JR, Kimoto E, Lai Y, Haglund U., and Artursson P (2012) Classification of inhibitors of hepatic organic anion transporting pol-ypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 55: 4740-4763.
22. Kimoto E, Yoshida K, Balogh L.M., Bi YA, Maeda K, El-Kattan A, Sugiyama Y, and Lai Y (2012) Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm 9: 3535-3542.
23. Köck K., Koenen A, Giese B., Fraunholz M, May K, Siegmund W., Hammer E, Völker U, Jedlitschky G., and Kroemer HK, et al. (2010) Rapid modulation of the organic anion transporting polypeptide 2B1 (OATP2B1, SLCO2B1) function by protein kinase C-mediated in-ternalization. J Biol Chem 285:11336-11347.
24. Kumar V, Prasad B, Patilea G., Gupta A, Salphati L, Evers R., Hop CE, and Unadkat JD (2014) Quantitative transporter proteomics by liquid chromatography with tandem mass spectrometry: addressing methodological issues of plasma membrane isolation and expression-activity relationship. Drug Metab Dispos 43:284-288.
25. Kunze A, Huwyler J, Camenisch G., and Poller B (2014) Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab Dispos 42:1514-1521.
26. Link E, Parish S, Armitage J., Bowman L, Heath S, Matsuda F., Gut I, Lathrop M, and Collins R; SEARCH Collaborative Group (2008) SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 359:789-799.
27. Ménochet K., Kenworthy KE, Houston J.B., and Galetin A (2012a) Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J Pharmacol Exp Ther 341:2-15.
28. Ménochet K., Kenworthy KE, Houston J.B., and Galetin A (2012b) Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos 40:1744-1756.
29. Michalski C, Cui Y, Nies A.T., Nuessler AK, Neuhaus P, Zanger UM, Klein K, Eichelbaum M., Keppler D, and Konig J (2002) A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 277: 43058-43063.
30. Niemi M, Pasanen MK, and Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181.
31. Ohtsuki S, Schaefer O, Kawakami H., Inoue T, Liehner S, Saito A., Ishiguro N, Kishimoto W, Ludwig-Schwellinger E, and Ebner T, et al. (2012) Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 40:83-92.
32. Poirier A, Cascais AC, Funk C, and Lavé T (2009) Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn 36: 585-611.
33. Prasad B, Evers R, Gupta A., Hop CE, Salphati L, Shukla S, Ambudkar S.V., and Unadkat JD (2014) Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos 42:78-88.
34. Prueksaritanont T, Chu X, Evers R., Klopfer SO, Caro L, Kothare PA, Dempsey C, Rasmussen S., Houle R, and Chan G, et al. (2014) Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol 78: 587-598.
35. Schaefer O, Ohtsuki S, Kawakami H., Inoue T, Liehner S, Saito A., Sakamoto A, Ishiguro N, Matsumaru T., and Terasaki T, et al. (2012) Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes. Drug Metab Dispos 40:93-103.
36. Shitara Y, Maeda K, Ikejiri K., Yoshida K, Horie T, and Sugiyama Y (2013) Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 34:45-78.
37. Tsamandouras N, Dickinson G, Guo Y., Hall S, Rostami-Hodjegan A, Galetin A, and Aarons L (2014) Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach. Clin Pharmacol Ther 96:90-100.
38. Varma MV, Lai Y, Kimoto E., Goosen TC, El-Kattan AF, and Kumar V (2013) Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res 30:1188-1199.
39. Vildhede A, Karlgren M, Svedberg E.K., Wisniewski JR, Lai Y, Norén A, and Artursson P (2014) Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. Drug Metab Dispos 42:1210-1218.
40. Watanabe T, Maeda K, Kondo T., Nakayama H, Horita S, Kusuhara H., and Sugiyama Y (2009) Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments. Drug Metab Dispos 37:1471-1479.
41. Zamek-Gliszczynski M.J., Lee CA, Poirier A, Bentz J., Chu X, Ellens H, Ishikawa T., Jamei M, Kalvass JC, and Nagar S, et al.; International Transporter Consortium (2013) ITC recommendations for transporter kinetic parameter estimation and translational modeling of transportmediated PK and DDIs in humans. Clin Pharmacol Ther 94:64-79.